India's drug price regulator has raised price caps on several medicines to address a nationwide shortage of critical cancer treatments [1].

The decision impacts patients relying on chemotherapy, as the scarcity of these drugs threatens the continuity of life-saving treatment cycles. Manufacturers had previously reduced production because the cost of raw materials exceeded the government-mandated price ceilings.

Between June 11 and 12, 2024, the National Pharmaceutical Pricing Authority announced a price-cap increase of 50 percent [2, 3]. This adjustment specifically targets platinum-based chemotherapy drugs, which have become difficult to source due to soaring raw platinum costs [1, 4].

While some reports focus on the two primary chemotherapy agents, cisplatin and carboplatin [2, 5], other records indicate the price adjustments apply to four drugs in total [6]. This expanded list includes the two cancer medications, and two anti-tetanus injections [6].

The shortage emerged as a direct result of the volatility in the platinum market. Because the regulator controlled the maximum retail price, pharmaceutical companies found it financially unsustainable to produce the drugs while paying higher prices for the raw minerals [1, 4].

By allowing the price caps to rise, the Indian government aims to incentivize manufacturers to resume full-scale production and stabilize the supply chain. This move seeks to ensure that patients in India can access necessary chemotherapy without facing prolonged delays, or inflated black-market prices [2, 3].

“India's drug price regulator has raised price caps on several medicines to address a nationwide shortage of critical cancer treatments.”

This policy shift highlights the tension between maintaining affordable healthcare and ensuring a stable drug supply. When government price controls do not account for global commodity price spikes—such as the cost of platinum—manufacturers may stop production to avoid losses, inadvertently creating public health crises. The 50 percent increase is a corrective measure to align domestic pricing with global economic realities to prevent treatment interruptions for cancer patients.